SHANK proteins: roles at the synapse and in autism spectrum disorder by Monteiro, Patrícia & Feng, Guoping
During development and throughout life, a number of 
dynamic processes regulate the number, size, shape and 
strength of neuronal synapses. These changes occur 
through alterations in the molecular composition of 
synapses and through the chemical modification 
of synaptic proteins1–4. However, sometimes, the genes 
encoding these synaptic proteins (such as those that 
encode SH3 and multiple ankyrin repeat domains 
protein 3 (SHANK3), neuroligin 3, neuroligin 4 or 
neurexin 1) carry particular mutations that result in 
the production of dysfunctional proteins that cannot 
fulfil their synaptic role. The consequences of such 
synaptic mutations often affect both protein structure 
and function, leading to synaptic and circuitry defects 
that may have a neurodevelopmental and neuro­
psychiatric impact.
Mutations in the SHANK (also known as ProSAP) 
family genes have been linked to syndromic and idio­
pathic autism spectrum disorder (ASD), as well as to 
other neuropsychiatric and neurodevelopmental dis­
orders (schizophrenia and intellectual disability)5–8. In 
mice, mutations in the genes encoding SHANK fam­
ily proteins (SHANK1, SHANK2 and SHANK3) often 
result in marked behavioural phenotypes. These include 
an increase in repetitive routines, altered social behav­
iour and anxiety­like phenotypes, seemingly similar 
to those described in some human neuro psychiatric 
disorders9.
Despite great research progress in establishing links 
between mutations in SHANK genes and ASD, the 
physio logical role of SHANK proteins has, until recently, 
been poorly understood. Here, we review the most 
recent studies that help to clarify the roles of SHANK 
proteins at the synapse, providing insightful mechanistic 
links to neuropsychiatric disorders.
The SHANK protein family
SHANK proteins are ‘master’ scaffolding proteins that 
tether and organize intermediate scaffolding proteins. 
They are located at excitatory synapses, where they are 
crucial for proper synaptic development and function1,10. 
In the mouse, SHANK proteins are encoded by Shank1, 
Shank2 and Shank3 genes. Downstream from their tran­
scription start sites, all three genes have alternative pro­
moter options, resulting in the generation of a wide array 
of mRNA transcripts and protein isoforms.
SHANK3. SHANK3 (also known as ProSAP2) is the 
best studied of the three SHANK protein family mem­
bers. The Shank3 gene is located on mouse chromosome 
15E3 (human location: 22q13.3), has 22 exons and spans 
60 kilobases of genomic DNA (FIG. 1). Shank3 has mul­
tiple intragenic promoters (probably six)8,11,12 and several 
alternative splicing exons (exon 11, exon 12, exon 18, exon 
21 and exon 22)12, resulting in the possible generation 
of several protein isoforms (see Supplementary infor­
mation S1 (figure)). Besides alternative promoter usage 
and mRNA splicing, Shank3 gene expression is regulated 
by epigenetic mechanisms such as DNA methylation and 
histone acetylation, causing tissue­specific expression of 
different SHANK3 isoforms13–15.
The full length structure of mouse SHANK3 con­
tains six domains for protein–protein interactions: 
according to information contained in the databases 
UniProt Knowledgebase (UniProtKb) and National 
Center for Biotechnology Information (NCBI) database 
of the National Library of Medicine at the US National 
Institutes of Health (see Further information). These 
domains comprise protein domain of unknown func­
tion 535 (DUF535), ankyrin repeat domain, SRC homo­
logy 3 (SH3) domain superfamily, postsynaptic density 
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Intragenic promoters
Promoters located within the 
body of the residing gene, 
regulating its activity. 
Intragenic promoters are 
mainly active in tissue-specific 
gene expression.
SHANK proteins: roles at the synapse 
and in autism spectrum disorder
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Abstract | Several large-scale genomic studies have supported an association between cases of 
autism spectrum disorder and mutations in the genes SH3 and multiple ankyrin repeat domains 
protein 1 (SHANK1), SHANK2 and SHANK3, which encode a family of postsynaptic scaffolding 
proteins that are present at glutamatergic synapses in the CNS. An evaluation of human genetic 
data, as well as of in vitro and in vivo animal model data, may allow us to understand how 
disruption of SHANK scaffolding proteins affects the structure and function of neural circuits and 
alters behaviour.
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Alternative splicing
A process whereby different 
mRNAs can be produced from 
a single gene through the 
differential incorporation of 
exons into the mature 
transcript during splicing. 
Frequently, various mature 
proteins are generated from  
a single gene.
Epigenetic mechanisms
A mechanism of a stable 
change in gene expression that 
does not involve changes in 
DNA sequence.
protein 95 (PSD95)–discs large homologue 1–zonula 
occludens 1 (PDZ) domain, proline­rich region (PRO) 
and sterile alpha motif (SAM). The amino­terminal 
ankyrin repeat domain (containing six ankyrin repeats) 
interacts with the PSD protein SHARPIN16 and probably 
binds to the cytoskeleton through an interaction with 
spectrin alpha chain, non­erythrocytic 1 (SPTAN1; also 
known as α­fodrin)17. However, the N­terminal region 
that precedes the ankyrin repeat domain interacts intra­
molecularly with the six ankyrin repeats and probably 
restricts the access to binding partners such as SHARPIN 
and SPTAN1 (REF. 18). The class  I PDZ domain of 
SHANK3 interacts with SAP90/PSD95­associated pro­
tein 1 (SAPAP1; also known as GKAP1)10 and the gluta­
mate receptor 1 (GluR1; also known as GRIA1) subunit 
of AMPA receptors (AMPARs)19, which is important 
for dendritic spine formation and synaptic transmis­
sion. The PRO domain binds to Homer20,21 and cort­
actin10 proteins, which are important for cytoskeleton 
regulation, synaptic transmission and plasticity. Last, 
the carboxy­terminal SAM domain of SHANK proteins 
is known to self­multimerize10,22 and is required for the 
localization of SHANK3 and SHANK2 to the PSD23. 
Besides all the aforementioned proteins, SHANKs have 
a number of other interaction partners8,24–27.
SHANK2. Shank2 (also known as ProSAP1) is the 
largest gene among Shank gene family members and 
is located on mouse chromosome 7F5 (human loca­
tion: 11q13.2). It has 25 exons and spans about 450 Kb 
of mouse genomic DNA (FIG. 1). SHANK2 contains 
five domains: ankyrin repeat domain (located at the 
N terminus), SH3, PDZ, PRO and SAM (located at 
the C terminus) (FIG. 1). There are three isoforms of 
SHANK2 that are produced by alternative promoter 
usage: SHANK2E (containing all five protein domains), 
SHANK2A (lacking the ankyrin repeat domain) and 
SHANK2C (lacking the ankyrin repeat domain and the 
SH3 domain) (see Supplementary information S2 (fig­
ure)). Another isoform, SHANK2B, is transcribed from 
the same intragenic promoter as SHANK2A but shows 
alternative splicing. SHANK2E is the longest isoform 
of SHANK2 and is the only isoform that contains the 
ankyrin repeat domain (which is thought to coordinate 
actin­dependent events at the apical membrane of epi­
thelial cells28). SHANK2E owes its name to the fact that 
it was initially thought to be expressed only in epithe­
lial cells28; however, recent data suggest that SHANK2E 
is also expressed in human and mouse brain tissue, 
with high expression levels in the cerebellum29,30. Like 
SHANK3 and SHANK1, SHANK2 is a scaffolding pro­
tein of the PSD that interacts with multiple partners at 
the synapse10,20,24.
SHANK1. Shank1 is located on mouse chromosome 
7B4 (human location: 19q13.33), has 24 exons and spans 
about 50 Kb of genomic DNA (FIG. 1). The gene contains 
two different promoters that can generate two differ­
ent protein isoforms: SHANK1A (the longest isoform, 
which contains ankyrin repeat domain, SH3, PDZ, PRO 
and SAM domains) and SHANK1B (which contains 
PDZ, PRO and SAM domains) (see Supplementary 
Figure 1 | Shank genes: structure and intragenic promoters. The schematics show the full structure of the mouse SH3 
and multiple ankyrin repeat domains protein (Shank) genes and the location of intragenic promoters within these genes 
(in the figure, indicated by the arrows with letters in blue boxes). These structures have been drawn on the basis of the 
information contained at the National Center for Biotechnology Information (NCBI) database and UniProt 
Knowledgebase (UniProtKb). The location of the protein domains is included above their respective encoding exons (in 
the figure, exons are numbered and colour coded). Please note that, for the Shank2 gene, some intron sequences have 
been deleted for simplicity. Each intron deletion is represented by a break symbol of 10 Kb, and the size of each total 
deletion in Kb is indicated above the respective break. ANK, ankyrin repeat domain; DUF535, protein domain of unknown 
function 535; PDZ, postsynaptic density protein 95–discs large homologue 1–zonula occludens 1 domain; PRO, 
proline-rich region; SAM, sterile alpha motif; SH3, SRC homology 3 domain superfamily.
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Shank3Shank2Shank1
a  Shank genes in the mouse brain
b  SHANK3 isoforms in the mouse brain
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The occurrence of a trait in 
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such as twins or siblings.
information  S3 (figure)). Besides these two tran­
scripts, which are produced by different promoters, 
Shank1 also contains alternative splicing sites that can 
generate different transcripts31. These include an iso­
form that lacks the C­terminal SAM domain, one that 
lacks the N­terminal ankyrin repeat domain and the 
SH3 domain, and one that does not contain ankyrin 
repeat domain, SH3 or SAM domains (these isoforms 
were originally called SHANK1B, SHANK1C and 
SHANK1D, respectively31).
CNS expression patterns. The expression pattern of the 
three members of the SHANK protein family is slightly 
different in the rodent brain. For example, SHANK3 
is the only family member that is highly enriched at 
cortico striatal glutamatergic synapses32. Shank1 mRNA 
seems to be exclusively expressed in the brain31 and is 
particularly enriched in the cortex, thalamus, amygdala, 
hippocampus (CA1 and CA3), dentate gyrus and in cer­
ebellar Purkinje cells9,33,34. Shank2 mRNA is enriched 
in the cortex, thalamus, hippocampus (CA1 and CA3), 
dentate gyrus and in Purkinje cells9. It is also expressed 
in the kidney and liver, at lower levels31. Shank3 mRNA is 
highly expressed in the heart and moderately expressed 
in the brain and spleen31. In the brain, Shank3 mRNA 
is enriched in the cortex, thalamus, striatum, hippo­
campus (more in CA3 than in CA1), dentate gyrus and in 
cerebellar granule cells9,35,36 (FIG. 2a).
The different SHANK3 protein isoforms are dif­
ferently expressed according to developmental stage, 
cell type and brain region11,13,35,37 (FIG. 2b), suggesting 
the existence of isoform­specific functions. The dif­
ferent isoforms also present different subcellular local­
izations11. SHANK3B (an isoform lacking the PRO 
and SAM domains) localizes to the nucleus, whereas 
SHANK3A, SHANK3C and SHANK3E (isoforms con­
taining the PRO and SAM domains) form clusters in the 
cytoplasm11. This data thus suggest that PRO and SAM 
domains might be important for nuclear targeting of 
SHANK3 isoforms and that different subcellular local­
izations might contribute to the existence of isoform­ 
specific functions. An important step for future research 
would be the generation of isoform­specific antibod­
ies or probes that could enable a systematic analysis of 
isoform­specific binding partners and iso form­specific 
brain expression patterns. Understanding SHANK3 
protein function from an isoform­specific perspec­
tive may also help to explain how different Shank3 
gene mutations may result in distinct phenotypic 
consequences.
Links between SHANK genes and ASD
Currently, 1 in 88 children in the United States is diag­
nosed with ASD, with the prevalence being 4–5 times 
greater in boys than in girls (1 in 54 boys compared with 
1 in 252 girls)38,39. Other genetic conditions such as fragile 
X syndrome, tuberous sclerosis and Down syndrome are 
often associated with ASD. ASD diagnosis in the DSM­5 
(Diagnostic and Statistical Manual of Mental Disorders, 
fifth edition40) is defined by social­communication 
and social­interaction deficits and narrow stereotyped, 
repetitive behavioural interests. These symptoms begin 
in early childhood and interfere with an individual’s 
daily activities.
The biggest evidence for a genetic contribution to 
ASD comes from twin studies, which show 31% concord-
ance rates for dizygotic twins and 88% for monozygotic 
twins41. ASDs are clinically heterogeneous, with symp­
tom severity ranging from mild social deficits with nor­
mal cognitive abilities to severe mental impairment and 
absence of language skills. Evidence points towards the 
involvement of a number of distinct genetic variations 
(including chromosomal rearrangements, copy number 
variations and coding sequence variants) that have been 
associated with many different genes42,43. Despite this 
heterogeneity, many of the implicated genes encode syn­
aptic proteins that have important roles in development 
or functioning of brain circuits (these include SHANK3, 
neuroligin 3, neuroligin 4 and neurexin 1)44,45. Thus, the 
evidence suggests that, although ASDs are aetio logically 
heterogeneous (and the disorder may involve polygenic, 
monogenic and environmental factors), synaptic dysfunc­
tion might well be a common underlying mechanism for 
a defined subset of ASDs.
Figure 2 | Expression patterns of Shank genes and SHANK3 isoforms.  
a | The schematics illustrate CNS expression pattern of SH3 and multiple ankyrin repeat 
domains protein (Shank) genes in the mouse brain. Each Shank gene is indicated by  
a different colour. Higher colour intensity represents a stronger expression signal 
(enriched areas). This part is created using data from REFS 9,11,31–34. b | The table 
details the expression pattern of different SHANK3 isoforms in the mouse brain. 
SHANK3B is expressed throughout the brain at low levels. SHANK3A and SHANK3E are 
enriched in the striatum and are present in the cortex, hippocampus, thalamus and 
amygdala. SHANK3C and SHANKD are mainly enriched in the cerebellum. SHANK3F is 
not represented, as no information on its expression is currently available. Hippocampal 
neurons strongly express all major isoforms of SHANK3, whereas astrocytes express low 
levels of SHANK3A, SHANK3C, SHANK3D and SHANK3E. Isoform expression pattern is 
extrapolated from REF. 11.
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Ring chromosomes
Structural aberrations of 
chromosomes, the long and 
short arms of which fuse 
together to form a ring. Ring 
chromosomes can have 
variable size and genetic 
content and are often 
associated with large terminal 
deletions.
Interstitial deletions
The loss of one or more 
segments of DNA within  
a single chromosome 
(intra-chromosomal deletion), 
thereby joining genes that were 
previously far apart.
Unbalanced translocations
Translocations are 
chromosomal abnormalities 
that are characterized by place 
exchange of parts of two or 
more different chromosomes. 
Balanced translocations have 
no net loss or gain of any 
chromosomal material, 
whereas unbalanced 
translocations have unequal 
exchange of chromosomal 
material, hence resulting in loss 
or gain of extra genes.
SHANK genes were first implicated in neurodevel­
opmental disorders by studies of Phelan–McDermid 
syndrome (PMS), a neurodevelopmental disorder that 
is caused by a 22q13.3 deletion and is characterized 
by autistic­like behaviours, hypotonia and delayed or 
absent speech46–48. Genomic rearrangements in patients 
with PMS include deletions, ring chromosomes, interstitial 
deletions and unbalanced translocations5,49. SHANK3 is 
deleted in nearly all reported cases of PMS50,51, and its 
disruption is therefore thought to cause the core neu­
rodevelopmental and behavioural deficits that are seen 
in patients. Supporting the idea that core PMS symptoms 
are due to SHANK3 haploinsufficiency46, individuals 
carrying a ring chromosome 22 in which the SHANK3 
gene is intact are phenotypically normal.
Apart from the syndromic forms of autism (such as 
PMS, in which SHANK3 disruption may be responsible 
for the core phenotype), many SHANK3 mutations have 
also been identified in genetic screenings of patients 
with ASD who have not been diagnosed with PMS5–7,52,53 
(TABLE 1; see Supplementary information S4 (table)). 
These mutations include microdeletions, nonsense muta­
tions, breakpoints and missense mutations. In addition, 
mutations in SHANK1 and SHANK2 have also been 
recently associated with ASD cases5,8,12,25,54. A meta­ 
analysis study found that mutations or disruptions in the 
SHANK gene family account for ~1% of all patients with 
ASD5. There is also a correlation between SHANK1–3 
mutations and the degree of cognitive impairment: 
patients with SHANK3 mutations have more­severe 
cognitive deficits than those with SHANK1 or SHANK2 
mutations5. Together these findings indicate that a com­
mon neurobiological role, shared by all SHANK gene 
family members, may be of relevance to ASD patho­
physiology and that the degree of cognitive impairment 
in ASD may depend on which SHANK family member 
is mutated. The difference in impairment severity might 
be explained by the expression pattern of the particu­
lar SHANK gene that is mutated and by the extent to 
which the other two remaining SHANK members can 
(or cannot) compensate for its loss. In addition, these 
findings indicate that mutations in SHANK genes are a 
potential monogenic cause for ASD and indicate that 
several SHANK mutations are of a syndromic nature 
and should be considered for screening in clinical prac­
tice5. Last, it is worth noting that many of the human 
SHANK3 mutations map to exon 21 and are associated 
with moderate to severe intellectual disability5. It is cur­
rently unclear how mutations in the PRO domain of 
exon 21 might be related to the pathophysiology. One 
possible explanation is that exon 21 is present in most 
SHANK3 isoforms; thus, mutations in this exon are 
likely to affect the expression and/or function of a large 
proportion of the SHANK3 proteins that are produced.
Given the potential importance of these genes in 
ASD, it is crucial to understand more about their nor­
mal roles at the synapse and how they are disrupted by 
mutations.
Table 1 | Human SHANK3 mutations and small deletions
Exon and domain 
affected by mutation
Total number of cases 
across studies
Diagnoses Phenotypes and comments Refs
Exon 21; PRO 11 ASD (7 cases), 
PDD-NOS (1 case), 
schizophrenia (3 cases)
• Severe ID (8 cases); mild–moderate ID (3 cases)
• Non-verbal (4 cases); severely impaired speech (2 cases)
• Global developmental delay (6 cases)
• Hypotonia (3 cases); ataxia and dysmetria (1 case)
• Cycling vomiting (1 case); gastroesophageal reflux (2 cases)
• Epilepsy (2 cases)
5,7, 
53,83
Exon 11; SH3 1 ASD Patient also carries mutation in NRXN1 gene 7
Exon 4; ANK 1 ASD • Sensitive to touch
• Developmental delay
• Seizures
• Echolalia
7
Intron 15–exon 16 
boundary
1 Asperger syndrome Behavioural problems and echolalia at the age of 2 years 7
Exon 19–intron 19 
boundary
1 ASD Patient ASQ score: 23 6
Exon 2 1 PDD-NOS Language deficiency around 18 months of age 6
Exon 1 1 ASD • Absence of language and severe ID
• High pain threshold and low noise threshold
• Impaired non-verbal communication and social interaction
• Motor stereotypies
53
Exon 8; ANK 2 ASD • Repetitive behaviours and circumscribed interests
• Generalized hypotonia and brisk reflexes
• Impaired verbal communication and social interaction
• Abnormal EEG
52,53
Please note that this table does not cover all known mutations. For other human SH3 and multiple ankyrin repeat domains protein 3 (SHANK3) mutations and 
deletions, see REFS 5,12. A more detailed table is provided as Supplementary information S4 (table). ANK, ankyrin repeat domain; ASD, autism spectrum disorder; 
ASQ, Autism Screening Questionnaire (a score higher than 15 indicates ASD); EEG, electroencephalography; ID, intellectual disability; NRXN1, neurexin 1; 
PDD-NOS, pervasive developmental disorder, not otherwise specified; PRO, proline-rich region; SH3, SRC homology 3 domain superfamily.
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Microdeletions
Small interstitial deletions of 
DNA (up to 5 Mb).
Breakpoints
The specific sites of 
chromosomal breakage that 
are associated with a particular 
chromosomal rearrangement.
Role in synaptogenesis and function
Glutamatergic synapses in the CNS are character­
ized by an electron dense thickening underneath the 
post synaptic membrane, the PSD. The PSD contains 
more than a thousand proteins, including membrane­ 
tethered receptors and channels (such as NMDA recep­
tors (NMDARs), metabotropic GluRs (mGluRs) and 
AMPARs), adaptor and scaffolding proteins (such as 
SAPAP and SHANK proteins), cytoskeletal and cell 
adhesion proteins (such as actin and neuroligins) and 
signalling molecules (such as calcium/calmodulin­ 
dependent protein kinase type II (CaMKII)). Together, 
these create a wide macromolecular complex55,56.
At the heart of the PSD lies the membrane­associated 
guanylate kinase (MAGUK) family, the key organizers 
of vertebrate CNS synapses. MAGUKs are modular 
proteins that are composed of multiple domains that 
enable protein–protein interactions, such as PDZ, SH3 
and C­terminal guanylate kinase domains. MAGUK 
members include PSD95 (also known as SAP90 or 
DLG4), SAP102 (also known as DLG3), SAP97 (also 
known as DLG1) and PSD93 (also known as chapsyn 
110 or DLG2). Together, these family members build 
up a dense scaffold that serves as interface between clus­
tered membrane­bound receptors, cell adhesion mole­
cules and the actin cytoskeleton57. The identification of 
MAGUK proteins, and the subsequent cloning of their 
associated proteins, has extended our comprehension of 
the molecular composition of the PSD1,57,58.
PSD95 is probably the best characterized MAGUK 
protein of the PSD. It has a PDZ domain that interacts 
with NMDARs and a guanylate kinase domain in its C 
terminus that is linked to members of the SAPAP family 
of proteins. SAPAP proteins subsequently bind to the 
PDZ domain of members of the SHANK protein family. 
SHANK proteins then bind to the actin cytoskeleton and 
to Homer protein, which in turn interacts with mGluRs. 
Through these extended links, PSD95, SAPAP, SHANK 
and Homer proteins form a quaternary complex that 
brings together mGluR and NMDAR complexes in the 
PSD (FIG. 3). This functional link between NMDARs 
and mGluRs is likely to facilitate crosstalk between 
ionotropic and metabotropic glutamate receptors59.
On a subcellular level, SHANK proteins are located 
in a distal area of the PSD that extends up to 120 nm 
away from the postsynaptic membrane10,60. Recent data 
suggest that there are two pools of SHANK proteins in 
the PSD complex: one that is closer to the postsynaptic 
membrane and that seems to be relatively stable and able 
to bind to SAPAPs, and another, more dynamic, pool 
that is present at a distal location and probably cannot 
interact with SAPAPs61.
Consistent with the roles of SHANK proteins as major 
scaffolding proteins in the postsynaptic site, the deletion 
of Shank genes in mice alters the PSD levels of several pro­
teins including Homer, SAPAP proteins, NMDARs and 
AMPARs9,37. Parallel to these molecular alterations, mor­
phological and functional changes have also been found in 
several Shank­mutant mice. Depending on which Shank 
gene is mutated and on the specific nature of the mutation, 
many other functional and behavioural consequences 
can be seen. These include impaired social behaviours, 
self­grooming and synaptic plasticity defects9,30,36,37,62–68 
(for a detailed comparison between Shank1­, Shank2­ and 
Shank3‑mutant mice, see REFS 8,12). Deletion of Shank 
genes also affects spine numbers and size37,66,69,70, as well 
as AMPA transmission (with effects on miniature excita­
tory postsynaptic current (mEPSC) frequency and ampli­
tude being observed)9,36,37,66,71. The different mutant mice 
thus indicate an important role of SHANK proteins in 
regulating excitatory neurotransmission.
Owing to the strong genetic association between 
SHANK3 mutations and ASD (see above), many neuro­
biology studies have focused on this particular gene. 
Shank3­knockout (Shank3­KO) mice display reduced 
corticostriatal connectivity and reduced striatal mEPSC 
frequency in adults9,36,37,66. This suggests that loss of 
Shank3 decreases the number of striatal afferents that 
are formed during development (resulting in a reduced 
number of corticostriatal synapses); however, recent 
electro physiological data obtained at postnatal day 14 
Figure 3 | SHANK-interacting proteins in the postsynaptic sit . A representatio  of  
a SH3 and multiple ankyrin repeat domains protein (SHANK) located in the postsynaptic 
density (PSD) is shown, with its protein–protein interaction domains illustrated. The 
N-terminal ankyrin repeat domain (ANK) interacts with the PSD protein SHARPIN and 
probably binds to the cytoskeleton through an interaction with spectrin alpha chain, 
non-erythrocytic 1 (SPTAN1). The PSD protein 95 (PSD95)–discs large homologue 1–
zonula occludens 1 (PDZ) domain interacts with SAP90/PSD95-associated proteins 
(SAPAPs) and the glutamate receptor 1 (GluR1) subunit of AMPA receptors (AMPARs). 
SAPAPs bind to PSD95, which then interacts with NMDA receptors (NMDARs). The 
proline-rich domain (PRO) binds to Homer (which binds to metabotropic GluRs 
(mGLuRs)) and cortactin proteins (which interact with actin and are important for 
cytoskeleton regulation). Last, the C-terminal sterile alpha motif (SAM) of SHANK 
proteins is known to self-multimerize and is required for the localization of  
SHANK proteins to the PSD. SH3, SRC homology 3 domain superfamily.
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Perineuronal nets
Aggregates of extracellular 
matrix molecules that embed 
cell bodies, axon initial 
segments and proximal 
dendrites of a subset of 
neurons in a mesh-like 
structure.
Excitation/inhibition (E/I) 
ratio
The relationship between 
synaptic excitation and 
inhibition, two opposing forces 
in terms of neurotransmission.
Multisensory integration
The neural processes that are 
involved in synthesizing 
information from cross-modal 
stimuli.
reveal that Shank3­KO mice actually exhibit increased 
striatal mEPSC frequency in early development71. These 
results indicate that there is a premature increase in (and 
subsequent arrest of) the development of excitatory affer­
ents onto striatal neurons in the absence of SHANK3 
(REF. 71). Given this reduction in basal excitatory synap­
tic transmission, one could mistakenly assume that there 
is reduced activity in the striatum of Shank3­KO mice. 
In fact, Shank3­KO mice have increased in vivo activity 
in the striatum36,71. This striatal hyperactive profile does 
not seem to be due to increased intrinsic excitability of 
striatal neurons but rather to be a downstream conse­
quence of increased cortical activity71. The mechanism 
behind the cortex hyperexcitability profile in the absence 
of SHANK3 is currently not known.
Corroborating these in vivo mouse studies, recent 
in vitro data also show increased frequency of evoked fir­
ing in cultured neurons from Shank3­KO mice72, as well 
as similar changes in cultured human neurons differenti­
ated from induced pluripotent stem cells that are derived 
from the cells of patients with PMS72,73. Although these 
studies have focused on excitatory transmission (owing to 
the location of SHANK3 at excitatory synaptic sites), it is 
important to keep in mind that Shank3 deletion may also 
affect inhibitory synaptic transmission. Indeed, recent 
data show reduced numbers of synaptic puncta con­
taining parvalbumin (PV; an interneuron marker in the 
cortex) and compromised wisteria floribunda agglutinin­ 
containing perineuronal nets that have reduced size and 
intensity in the insular cortex74, as well as reduced PV 
expression in the striatum75. In the cortex, perineu­
ronal nets preferentially enwrap large PV­containing 
interneurons. Therefore, when perineuronal nets are 
disrupted, the perisomatic inhibition of the targets of 
these interneurons is reduced. This indicates an imma­
ture or altered inhibitory circuitry in Shank3­KO mice. 
In line with these data, a different study found that the 
abnormal network firing pattern that is seen in cultured 
cortical neurons of Shank3­KO mice can be normalized 
by application of clonazepam, an enhancer of GABA­
mediated inhibitory transmission76. Taking a different 
approach35, it has also been shown that mice carrying a 
deletion in Shank3 exon 9 have an increased excitation/
inhibition (E/I) ratio in the medial prefrontal cortex (mPFC). 
Although these mice have decreased miniature inhibi­
tory postsynaptic currents (mIPSC) frequency in mPFC 
layer 2/3 pyramidal neurons, they display increased 
mIPSC frequency in hippocampus CA1 pyramidal neu­
rons. Together, these studies suggest a developmental 
arrest of neural circuits in the absence of SHANK3, with 
consequent disruption of optimal E/I circuitry balance77.
Given the wide array of synaptic roles of SHANK3 
that are demonstrated by these studies (ranging from 
scaffolding to regulating spine morphology and neuro­
transmission), it will be important to understand which 
role is the most significant with regard to ASD.
Neurobiology of SHANK proteins in ASD
As noted above, several human genetic studies have 
pointed towards a link between mutations in SHANK1, 
SHANK2 or SHANK3 and ASD5,78. Although ASD 
neuropathology remains elusive, animal models based on 
mice carrying relevant genetic mutations may help us to 
dissect the circuit basis of behaviours that are evolution­
ary conserved and relevant to ASD. Several behavioural 
abnormalities have been reported in mice with deletions 
in Shank genes, some of which are considered ASD­like 
behaviours9,30,62–65,67,68. Thirteen different mutant mouse 
lines carrying Shank3 deletions have been generated so 
far (TABLE 2; see Supplementary information S5 (table)). 
Of these, 9 of 13 mutant lines show aberrant social behav­
iours (1 line has not been tested for these behaviours), 
and 9 of 13 display repetitive self­grooming behaviour 
(TABLE 2). Self­injurious grooming is usually observed 
after complete Shank3 deletion71 and after Shank3 PDZ­
targeted disruption9,37,66. A key challenge is therefore 
to understand how the disrupted synaptic function of 
SHANK3 can lead to these behavioural changes.
Social interaction requires the ability to combine 
sensory information with emotional and cognitive con­
tent79. Many brain areas have been implicated as part of 
the ‘social brain’, including the mPFC, the amygdala, the 
anterior insula, the anterior cingulate cortex, the infe­
rior frontal gyrus and the superior temporal sulcus80–82. 
A recent study of the mouse insular cortex found multi-
sensory integration deficits in Shank3­mutant mice and 
suggested that altered GABA circuits in the insular 
cortex may underlie the asocial urges of these mice74.
Other behavioural parameters, such as ultrasonic 
vocalizations and learning and memory, have been 
evaluated in some of the different Shank3­mutant 
lines, revealing distinct results that might be related to 
isoform­specific disruptions in each line (TABLE 2). Indeed, 
the idea that isoform­specific disruptions will result in 
different phenotypic consequences (and even result 
in different disorders) has recently gained momentum. 
A recent study66 generated two novel Shank3­mutant 
mouse lines harbouring Shank3 mutations that are 
found in patients with ASD53 and schizophrenia83, 
respectively. Both mutations are located in exon 21 of 
the mouse Shank3 gene, and the mutations are located 
only 325 nucleotides apart. The ASD­linked InsG3680 
mutation has a guanine nucleotide insertion at position 
3680 of Shank3 cDNA, resulting in a frameshift muta­
tion and the appearance of a stop codon immediately 
after the mutation. The schizophrenia­linked R1117X 
mutation, on the other hand, changes arginine 1117 to 
a stop codon. These two mutant mouse lines exhibit 
both distinct and shared defects at molecular, synaptic, 
circuit and behavioural levels66. Whereas mice with the 
ASD­linked mutation display impaired striatal synaptic 
transmission at postnatal day 14 and abnormal juvenile 
social interactions (similar to the early­age onset of ASD 
symptoms), adult mice with the schizophrenia­linked 
mutation have profound synaptic defects in the PFC 
and display social dominance behaviour. Given that the 
ASD­linked mutation results in almost complete loss of 
SHANK3 (similar to a full deletion of the Shank3 gene) 
and that the schizophrenia­linked mutation results in 
the generation of a truncated SHANK3 protein (which 
could be either partially functional or act as a dominant 
negative), this study provides, for the first time, some 
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Table 2 | Characterization of the different Shank3-mutant mice
Protein 
domain/ 
exon 
mutated
Phenotype Refs
Altered 
synaptic 
proteins
Spine 
morphology
Social 
behaviour
USVs Repetitive 
behaviours
Learning 
and 
memory
Motor 
coordination
Other
ANK; exons 
4–9
GluR1 Defective 
remodelling
Reduced 
sniffing
Reduced Increased 
self-grooming
MWM test 
normal
Impaired NOR test 
impaired
63, 
64
SAPAP1,  
Homer 1b/c, 
GluR1 and 
GluN2A
Reduced 
density
Abnormal 
interactions
Altered Increased 
self-grooming 
and head 
pokes in 
hole-board 
test
MWM test 
impaired
Impaired Reduced 
distance in OF 
test; NOR test 
impaired
62
GluR2, GluR3, 
Homer 1b/c and 
PSD95
NA Mild 
impairment
Increased Increased 
self-grooming
MWM test 
slightly 
impaired
NS NOR test 
impaired
101
ANK; exons 
4–7
NA NA Abnormal 
social 
novelty
NA No increase in 
self-grooming
NA NA NA 9
ANK; exon 
9
NA NA Normal Normal Increased 
rearing 
in novel 
environment
Normal NA None 35
PDZ; exons 
13–16
Homer 1, 
SAPAP3, 
GluN2A, 
GluN2B, GluR2 
and PSD93
Reduced 
density
Abnormal NA Self-injurious 
grooming
Normal NA Increased 
anxiety-like 
behaviour
9
Homer 1, 
SAPAP3, 
GluN2A, GluN2B 
and GluR2
Reduced 
density
Abnormal NA Self-injurious 
grooming
NA Impaired Increased 
anxiety-like 
behaviour
37
SH3; exon 
11
GluN2B, 
SHANK2, 
Homer 1b/c and 
mGluR5
Normal Abnormal NA Self-injurious 
grooming
MWM test 
impaired
Minor deficits Hyposensitivity; 
impaired 
nesting and 
marble burying; 
increased 
aggression
30, 
98
PRO; exon 
21
mGluR5 Normal Abnormal 
social 
novelty
NA Increased 
self-grooming
MWM test 
impaired
Impaired Hypersensitivity; 
impaired 
nesting and 
marble burying; 
anxiety-like 
behaviour
65
p-GluN2B 
Tyr1472
NA Inconclusive 
testing
NA None MWM 
test mildly 
impaired
Impaired Impaired 
nesting and 
marble burying; 
anxiety-like 
behaviour
102
Homer proteins, 
SAPAP3, 
SYNGAP, 
GluN1, GluN2A, 
GluN2B, GluR2 
and mGluR5
Reduced 
number
Abnormal Normal Self-injurious 
grooming
NA Impaired Anxiety-like 
behaviour; PPI 
test impaired; 
startle-response 
impaired
66
All 
domains; 
exons 4–22
Pan-SAPAP, 
SAPAP3 and 
Homer 1b/c
Reduced in 
the striatum
Normal Altered 
spectral 
properties
Self-injurious 
grooming
MWM test 
impaired
Impaired Anxiety-like 
behaviour; PPI 
test impaired; 
impaired 
instrumental 
learning
36
A more detailed table is provided as Supplementary information S5 (Table). ANK, ankyrin repeat domain; GluR1, glutamate receptor 1; mGluR5, metabotropic 
GluR5; Homer 1b/c, Homer splice variants 1b and 1c; MWM, Morris water maze; NA, not available; NOR, novel-object recognition; NS, nonsignificant; OF, open 
field; p-GluN2B Tyr1472, phosphorylated Tyr1472 site of GluN2B; PDZ, postsynaptic density protein 95 (PSD95)–discs large homologue 1–zonula  
occludens 1 domain; PPI, prepulse inhibition; PRO, proline-rich region; SAPAP1, SAP90/PSD95-associated protein 1; SH3, SRC homology 3 domain superfamily; 
SHANK2, SH3 and multiple ankyrin repeat domains protein 2; USVs, ultrasonic vocalizations.
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neurobiological insights into how different mutations in 
the Shank3 gene may lead to mutation­specific defects 
and contribute to different disorders.
Besides isoform­specific mutations, SHANK3 gene 
expression (or perhaps expression of specific isoforms) 
seems to be crucial. For example, duplications of 22q13 
that span SHANK3 have been reported in patients 
diagnosed with attention deficit hyperactivity disorder 
(ADHD)52, and mice in which SHANK3 is overexpressed 
exhibit synaptic dysfunction and manic­like phenotypes84.
Mutant mice carrying Shank1 and Shank2 deletions 
have also been generated and characterized in recent 
years67,85–87,68,88,30,89 (TABLE 3; see Supplementary infor­
mation S6 (table)). In line with the human genetic data 
that showed an association between different SHANK 
family members and distinct cases of ASD5, all three 
lines of mutant mice carrying Shank1 and Shank2 
deletions display certain ASD­like phenotypes, such 
as increased repetitive behaviour and/or decreased 
social interaction30,67,68. A recent study reveals that, 
besides regulating excitatory synaptic transmission in 
neurons67, SHANK1 also regulates excitatory synaptic 
transmission in inhibitory interneurons86. The study 
further confirms the expression of all three Shank genes 
in CA1 PV­expressing interneurons and suggests that, in 
the absence of Shank1, a shift occurs in the E/I balance 
of the hippocampus. As a consequence, PV­expressing 
interneurons receive less excitatory input and provide 
weaker inhibitory output onto CA1 pyramidal neurons. 
Interestingly, no major changes were found in CA1 
inhibitory synapses in Shank2­mutant mice with regard 
to inhibitory transmission30 or protein markers68.
Although the different Shank1­, Shank2­ and 
Shank3­mutant mice have some distinct phenotypes 
at the molecular and functional level, they all feature a 
disrupted E/I balance that results from initial changes 
in excitatory synaptic transmission and composition, as 
well as ASD­relevant behavioural phenotypes30,67,68. Taken 
together, the findings from different Shank­mutant mice 
suggest that each Shank mutation might underlie a 
defined subset of ASD pathology and contribute to the 
myriad of phenotypes that are seen in patients.
Towards the development of treatment
Given the complex genomic landscape of human muta­
tions that are associated with ASD, animal models pose a 
starting point to study the neurobiology of specific muta­
tions and establish useful genotype–cellular phenotype 
correlations. The SHANK3 gene, in particular, has the 
advantage of having available 13 difference mice models, 
harbouring different Shank3 gene disruptions. The gene 
itself is probably also less complicated to study than some 
other ASD­related genes because of the defined locali­
zation of SHANK3 protein at glutamatergic synapses. 
This has advantages over the study of a transcription 
factor, such as methyl­CpG­binding protein 2 (MeCP2), 
which may directly regulate the expression of hundreds 
of genes. Because ASDs are neurodevelopmental disor­
ders (patients typically display symptoms before the age 
of three)90,91, one of the key questions in autism research 
is whether the pathology is reversible in adults. Recently, 
this question was tackled in a study that generated a 
Shank3 conditional knock­in mouse37. These mice are 
born as Shank3­KO (carrying a PDZ domain dele­
tion) but have a FLExed PDZ domain inverted, which 
allows reorientation at any time point in life to restore 
the Shank3 gene. This strategy design is crucial because 
it keeps the Shank3 gene under the control of its endo­
genous genomic locus and avoids SHANK3 expression 
at non­physiological levels that could induce potential 
confounds. These Shank3­KO mice have deficits in stri­
atal neurotransmission, reduced spine density in the 
striatum and reduced levels of PSD proteins (SAPAP3, 
Homer, GluN2A, GluN2B and GluR2) in the striatum. 
All these alterations can be reverted in the adult by restor­
ing the Shank3 gene. Behaviourally, these Shank3­KO 
Table 3 | Characterization of the different Shank1- and Shank2-mutant mice
Protein 
domain/ 
exon 
mutated
Phenotype Refs
Altered 
synaptic 
proteins
Spine 
morphology
Social 
behaviour
USVs Repetitive 
behaviours
Learning 
and 
memory
Motor 
coordination
Other
Shank1 PDZ; 
exons 14–15
SAPAP and 
Homer proteins
Reduced 
density
Inconclusive 
testing
Reduced No increase in 
self-grooming
Enhanced 
in radial 
maze
Impaired Anxiety-like 
behaviour
67,85, 
87
Shank2 PDZ; 
exons 16–17
p-CaMKII α/β, 
p-ERK1/2, 
p-p38, p-GluR1 
(S831 and 
S845), GABAA2R; 
increased 
GluN1
NS Abnormal Reduced Repetitive 
jumping
MWM test 
impaired
NA Anxiety-like 
behaviour
68,88
Shank2 PDZ; 
exon 17
Increased 
GluN1, GluN2A, 
GluN2B, GluR2 
and SHANK3
Reduced 
density
Abnormal Abnormal Increased 
self-grooming
MWM test 
impaired
NS Hyperactivity 30,88
A more detailed table is provided as Supplementary information S6 (table). GABAA2R, GABA type A2 receptor; MWM, Morris water maze; NA, not available; NS, 
nonsignificant; p-CaMKII α/β, phosphorylated calcium/calmodulin-dependent protein kinase type II subunit alpha/beta; p-ERK1/2, phosphorylated extracellular 
signal-regulated kinases 1 and 2; p-GluR1, phosphorylated glutamate receptor 1; PDZ, postsynaptic density protein 95 (PSD95)–discs large homologue 1–zonula 
occludens 1 domain; SAPAP, SAP90/PSD95-associated protein; Shank1, SH3 and multiple ankyrin repeat domains protein 1; USVs, ultrasonic vocalizations.
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mice display repetitive self­injurious grooming, anxiety, 
social­interaction deficits (reduced social­interaction fre­
quency and duration) and impaired motor coordination. 
After adult restoration of Shank3 expression, repetitive 
self­injurious grooming and social­interaction deficits, 
but not anxiety or motor coordination deficits, can be 
rescued, indicating a selective rescue of certain autism­
like phenotypes. The same study shows that the behav­
ioural deficits that are irreversible in adulthood can be 
improved by early postnatal intervention, highlighting 
the unique behavioural effects of SHANK3 expression 
during specific developmental periods and through­
out life. Given the emergence of new genome editing 
approaches (such as CRISPR), these results suggest that 
repair of the SHANK3 gene in adulthood could alleviate 
some of the synaptic and behavioural impairments that 
are associated with SHANK3 mutations. Although there 
are still technical limitations to the genetic manipulation 
of mature neurons in a fully formed brain, new studies 
have been pushing the boundaries of the use of CRISPR 
in adult brain repair92. More importantly, this study 
suggests the possibility of treatment (whether pharma­
cological or through future genetic repair approaches) 
for patients with SHANK3 mutations or deletion, during 
adulthood. Similar encouraging adult­rescue results have 
been reported for mutant mice carrying deletions and 
duplications in other ASD­related genes such as Mecp2 
(REFS 93–95) and ubiquitin­protein ligase E3A (Ube3a)96.
Other studies have taken a different approach towards 
reversing the phenotype resulting from SHANK3 
deficiency. In one study97, the phosphoproteome of 
SHANK3­deficient rat cortical neurons was character­
ized, revealing an upregulation of CDC­like kinase 2 
(CLK2) expression. Inhibition of CLK2 rescued social 
behaviour in mice carrying a mutation in Shank3 
exon 21, as well as synaptic deficits in SHANK3­deficient 
neurons and neurons derived from patient with PMS.
Together, these studies suggest that adult restoration 
of SHANK3 levels or restoration of downstream medi­
ators may be a useful approach to alleviate some of the 
synaptic and behavioural impairments that are associ­
ated with SHANK3 mutations. Aligned with the idea of 
targeting downstream mediators and proteins associated 
with SHANK3 network, two groups have recently looked 
into mGluR5 and Homer as potential therapeutic targets 
in ASD. Using a complete Shank3­KO mouse36, it was 
shown that antagonism of mGluR5 activity ameliorates 
over­grooming behaviour, whereas positive allosteric 
modulation of mGluR5 exacerbates self­grooming. In a 
second study98, it was reported that a pharmacological 
increase in mGluR5 activity ameliorates over­grooming 
behaviour and rescues other behavioural deficits in 
Shank3­KO mouse. Although these studies might, at 
first, seem to be discrepant — the mGlu5R positive ago­
nist CDPPB exacerbates and ameliorates self­grooming 
in the respective studies — it is crucial to note that these 
results were derived from different Shank3­mutant mouse 
lines. Furthermore, the results of the two studies were 
otherwise in agreement. In one study, CDPPB treatment 
slightly improved instrumental learning, normalized 
striatal long­term depression and slightly increased the 
protein level of two splice variants of Homer (Homer 1b 
and Homer 1c) in the striatum of complete Shank3­KO 
mouse36. Similarly, in the other study98, a pharmacolog­
ical increase in mGluR5 activity ameliorated functional 
deficits (NMDA­induced membrane depolarization) 
and behavioural defects (social interaction and Morris 
water maze performance) in mice with deleted exon 11. 
Nevertheless, these studies suggest that the defects in 
downstream signalling, and thus potential therapeutic 
targets (such as mGluR5 and Homer), that result from dif­
ferent mutations of the same gene might be very different.
In an unrelated study99, the authors reported a marked 
loss of cortical actin filaments in mice with deleted 
exon 11, which was associated with reduced RAC1 and 
PAK activity and increased cofilin activity (the major 
actin depolymerizing factor). This suggested that actin 
regulators might be another potential molecular target 
for the treatment of ASD. Elevation of RAC1 activity in 
the PFC of these mice rescued their social behaviour defi­
cits and NMDAR hypofunction, whereas inhibition of 
PAK or RAC1 function induced social behaviour deficits 
and NMDAR hypofunction in wild­type mice.
The aforementioned demonstrations of pharmaco­
logical reversals of phenotypes in Shank3­mutant mice 
highlight potential target pathways that seem to con­
verge with some pharmacological reversal studies car­
ried out in Shank2­mutant mice. In those studies68,100, 
NMDA hypofunction was suggested to be a potential 
mechanism underlying ASD­like behaviours. By treating 
Shank2­mutant mice with d­cycloserine (a partial ago­
nist of NMDAR), one study showed an improvement in 
social interaction that could also be attained by treating 
the mice with CDPPB (possibly because of the enhance­
ment of NMDAR function through mGluR5 activation)68. 
Similarly, another study used clioquinol (a zinc chelator 
and ionophore) to rescue social­interaction deficits in 
Shank2­mutant mice. It was suggested that clioquinol can 
be used to mobilize zinc towards postsynaptic sites, where 
it would then increase NMDAR function through tyros­
ine kinase SRC activation100. Alterations in NMDAR func­
tion and excitatory transmission could potentially lead to 
an E/I imbalance, as was also suggested by a recent study 
that showed impaired GABAergic neurotransmission in 
mice with deleted exon 6 and exon 7 (REF. 88). The study 
further demonstrated that administration of a GABAA 
receptor agonist can slightly improve the spatial­ memory 
deficits observed in Shank2­mutant mice, although the 
social­interaction deficits cannot be rescued. Together 
these studies suggest that NMDAR hypofunction con­
tributes to the development of some ASD­like phenotypes 
in Shank­mutant mice and that other related molecular 
targets could potentially be used to modulate NMDAR 
function and improve specific phenotypes.
Conclusions and future perspectives
Many important questions remain. Can we mitigate the 
loss of a missing SHANK protein by somehow upregu­
lating other SHANK protein family members? Which of 
the domains of SHANK proteins are essential for their 
roles? Which cell types are more vulnerable to SHANK 
protein loss?
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Although most of the human SHANK mutations 
that underlie clinical conditions are heterozygous, 
the study and characterization of Shank homozygous 
mutant mice is sometimes essential, as it allows us to 
gain a clear understanding of the physiological role of a 
particular gene and the functional consequences of its 
disruption. Overall, three very important conclusions 
can be drawn from all the aforementioned studies. ‘The 
earlier the better’ seems to be the case in terms of ther­
apeutic window; however, adult intervention may still 
be useful to alleviate some of the impairments that are 
associated with SHANK3 mutations. It is also clear that 
efforts need to be taken to understand Shank3 muta­
tions in an isoform­specific manner. Finally, careful 
genotype–phenotype patient stratification is required 
before individual testing of specific pharmacological 
agents. Shank­mutant animal models, together with 
patient­ derived induced pluripotent stem cells, will cer­
tainly help us to uncover some of the neurobiological 
secrets of SHANK proteins.
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